To explore the role of socioeconomic factors in the initiation of SGLT2 inhibitor therapy among patients with chronic heart failure, addressing health disparities in cardiovascular care.
Approach:
Data Source: Utilized the German Analysis Database for Evaluation and Health Services Research (DADB) and the INKAR database for demographic and socioeconomic indicators.
Study Population: Included individuals with full insurance coverage diagnosed with left ventricular failure or unspecified heart failure in 2023, excluding those with contraindications for SGLT2i therapy.
Medication and Outcome: Main outcome was the initiation of SGLT2i therapy (dapagliflozin and empagliflozin) in 2023.
Covariate Assessment: Assessed various covariates including age, gender, nationality, socioeconomic status, and health program enrollment.
Statistical Methods: Conducted multilevel logistic regression analysis to identify factors associated with SGLT2i initiation.
Key Findings:
Socioeconomic factors significantly influence the initiation of SGLT2i therapy in heart failure patients.
Disparities in prescription rates may exist based on individual and area-level socioeconomic status.
Interpretation:
The study highlights the need to understand how socioeconomic factors affect access to SGLT2i therapy in heart failure management.
Limitations:
The study is limited to claims data, which may not capture all relevant clinical information.
Exclusion of patients with contraindications may limit generalizability.
Conclusion:
Understanding the impact of socioeconomic status on SGLT2i initiation can inform strategies to improve access and adherence in heart failure care.
